CI

At a glance

ClinicalIndex Comparison Record
Phase 2Active· 30 enrolled
Drug / intervention
Durvalumab +2 moredrug
Likely dose
Durvalumab 1500 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT05092412
NCT05092412Phase 2Active
CompareCT.gov

A First-line Multi-center, Single-arm Exploratory Study Using Low-dose Radiotherapy (LDRT) Combined With Durvalumab (MEDI4736), Etoposide, and Cisplatin/Carboplatin for Patients With Extensive-stage Small Cell Lung Cancer

You Lu·interventional·Posted Oct 25, 2021·Updated May 8, 2026

In Brief

A Phase 2 clinical trial evaluating Low-dose radiotherapy, Durvalumab, and 1 other intervention for Lung Cancer and 2 related conditions. Active but no longer recruiting, targeting 30 participants across 3 sites.

Detailed Summary

The purpose of this study was to evaluate the efficacy of low-dose radiotherapy (LDRT) combined with durvalumab, etoposide, and cisplatin/carboplatin in the first-line treatment of extensive-stage small cell lung cancer.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLung Cancer, Extensive-stage Small-cell Lung Cancer, Durvalumab
CountriesChina
CollaboratorsAstraZeneca

Timeline

Phase 2Active
202220232024202520262027
First PostedOct 25, 2021
Enrollment StartMar 2, 2022
Primary CompletionFeb 6, 2023
Study CompletionJun 30, 2027
TodayJul 1, 2026
Enrollment to primary: 11 monthsPosted 4.7 years ago

Interventions

Low-dose radiotherapyradiation

The LDRT deals with primary tumour in a 15 Gy of 5fractions over five days, starting from Day 1 in the first cycle.

Durvalumabdrug

Durvalumab 1500 mg intravenous infusion, started to be used simultaneously with chemotherapy at week 0 and continued after chemotherapy.

Etoposide, and cisplatin/carboplatindrug

Starting from week 0, the dose of etoposide + carboplatin or cisplatin in the study will not exceed the dose for specific indications in the product instructions (etoposide \[80 to 100mg/m2\] via intravenous infusion and carboplatin \[ The area under the curve (AUC) is 5-6\] by intravenous infusion or cisplatin \[75-80 mg/m2\] by intravenous infusion), using up to 4 cycles. The choice of platinum drugs is at the discretion of the investigator.